San Diego-centered Viking Therapeutics marked alone as a serious competitor while in the weight loss drug marketplace in February following revealing promising details from the mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered as a weekly injection As well as in March the